News

SpineThera’s clinical development program for SX600 will evaluate sustained-release, injectable treatment options for pain in and near the spine Minneapolis, MN – August 22, 2019 - SpineThera, Inc., a privately held, clinical stage pharmaceutical company, announced today that the United States Patent and Trademark Office has issued Patent 10,350,222 related to its non-opioid, sustained-release drug technology.

Purdue will support SpineThera’s clinical development program to evaluate sustained-release, injectable treatment options for pain in and near the spine October 22, 2018 03:07 PM Eastern Daylight Time. STAMFORD, Conn. & PLYMOUTH, Minn.--(BUSINESS WIRE)--Purdue Pharma L.P. and SpineThera, Inc. today announced that the companies have entered into an agreement that provides Purdue the exclusive option to acquire SpineThera, Inc. and gain worldwide rights to its products and technology platforms, including lead asset SX600, a novel dexamethasone containing microsphere that is in development for epidural administration for low back pain. This technology has potential for development of non-opioid treatments for acute and chronic pain.

On October 10, 2017 the Mayo Clinic Center for Individualized Medicine, Destination Medical Center, and Medical Alley Association are hosting the Discovery Square Innovators + Investors Forum at the Mayo Civic Center.

SpineThera was featured in three news stories published by the Star Tribune about Minnesota companies working on non-opioid technologies to reduce pain.